4-氟-1H-吲哚-7-羧酸甲酯 | 313337-35-8

• 物质功能分类: 医药中间体 - 杂环化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-氟-1H-吲哚-7-羧酸甲酯
• 英文名称: methyl 4-fluoro-1H-indole-7-carboxylate
• 英文别名: methyl (4-fluoro)indole-7-carboxylate；4-fluoro-7-carbomethoxy indole
• CAS: 313337-35-8
• 化学式: C₁₀H₈FNO₂
• 分子量: 193.177
• InChiKey: HEQXLRSGYSDTAZ-UHFFFAOYSA-N

物化性质

• 沸点：
  335.6±22.0 °C(Predicted)
• 密度：
  1.341±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  42.1
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  4-氟-1H-吲哚-7-羧酸甲酯 在 水 、 sodium tert-pentoxide 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 52.0h， 生成 (racemic)-1-([1,1'-biphenyl]-4-ylmethyl)-N-(6-(cyanomethyl)spiro[3.3]heptan-2yl)-4-fluoro-1H-indole-7-carboxamide
  参考文献：
  名称：

  BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF

  摘要：

  提供了用于调节EP2和EP4受体活性的化合物、组合物和方法，以及用于治疗、预防和改善与EP2和EP4受体活性相关的疾病或疾病症状的一种或多种方法。在某些实施例中，这些化合物是EP2和EP4受体的拮抗剂。

  公开号：

  US20190315712A1
• 作为产物：
  描述：

  4-氟-7-氰基-吲哚 在 盐酸 作用下， 以 甲醇 、 苯 为溶剂， 反应 30.58h， 生成 4-氟-1H-吲哚-7-羧酸甲酯
  参考文献：
  名称：

  Inhibitors of HIV-1 attachment. Part 7: Indole-7-carboxamides as potent and orally bioavailable antiviral agents

  摘要：

  A series of substituted carboxamides at the indole C7 position of the previously described 4-fluoro-substituted indole HIV-1 attachment inhibitor 1 was synthesized and the SAR delineated. Heteroaryl carboxamide inhibitors that exhibited pM potency in the primary cell-based assay against a pseudotype virus expressing a JRFL envelope were identified. The simple methyl amide analog 4 displayed a promising in vitro profile, with its favorable HLM stability and membrane permeability translating into favorable pharmacokinetic properties in preclinical species. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.10.115

文献信息

• [EN] BICYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER<br/>[FR] COMPOSÉS BICYCLIQUES ET LEUR UTILISATION DANS LE TRAITEMENT DU CANCER
  申请人：TEMPEST THERAPEUTICS INC

  公开号：WO2018195123A1

  公开（公告）日：2018-10-25

  The present disclosure is directed to novel compounds of Formula I and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of cancer, including glioblastoma, bone cancer, head and neck cancer, melanoma, basal cell carcinoma, squamous cell carcinoma, adenocarcinoma, oral cancer, esophageal cancer, gastric cancer, intestinal cancer, colon cancer, bladder cancer, hepatocellular carcinoma, renal cell carcinoma, pancreatic cancer, ovarian cancer, cervical cancer, lung cancer, breast cancer, and prostate cancer. The compounds of the disclosure are selective antagonists of the EP4 receptor and useful treatment of various diseases that may be ameliorated with blockade of PGE2-mediated signaling.

  本公开涉及一种新型化合物I的化学式及其药用可接受的盐、溶剂化合物、盐的溶剂化合物和前药，用于预防（例如，延迟发病或减少发展风险）和治疗（例如，控制、缓解或减缓进展）癌症，包括胶质母细胞瘤、骨癌、头颈癌、黑色素瘤、基底细胞癌、鳞状细胞癌、腺癌、口腔癌、食管癌、胃癌、肠癌、结肠癌、膀胱癌、肝细胞癌、肾细胞癌、胰腺癌、卵巢癌、宫颈癌、肺癌、乳腺癌和前列腺癌。本公开的化合物是EP4受体的选择性拮抗剂，可用于治疗多种疾病，这些疾病可能通过阻断PGE2介导的信号传导而得到缓解。
• Indole, azaindole and related heterocyclic sulfonylureido piperazine derivatives
  申请人：——

  公开号：US20040006090A1

  公开（公告）日：2004-01-08

  This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with sulfonylureido piperazine derivatives of Formula I. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS. 1 wherein: Z is 2 Q is selected from the group consisting of: 3 —W— is 4 —represents a carbon-carbon bond or does not exist; and A is NR 13 R 14 .

  该发明提供了具有药物和生物影响特性的化合物，它们的药物组合物及使用方法。具体而言，该发明涉及式I的磺酰脲基哌嗪衍生物。这些化合物具有独特的抗病毒活性，无论是单独使用还是与其他抗病毒药物、抗感染药物、免疫调节剂或HIV进入抑制剂结合使用。更具体地，本发明涉及HIV和艾滋病的治疗。其中：Z是；Q是选择自组中的一种；—W—是；—代表碳-碳键或不存在；A是NR13R14。
• Indole, azaindole and related heterocyclic ureido and thioureido piperazine derivatives
  申请人：Regueiro-Ren Alicia

  公开号：US20060094717A1

  公开（公告）日：2006-05-04

  This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with ureido and thioureido piperazine derivatives of Formula I. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS. The compounds of Formula I are wherein: Y is O or S; Q is selected from the group consisting of m is 2; A is NR 13 R 14 ; and —W— is

  本发明提供了具有药物和生物影响性质的化合物，它们的制药组合物和使用方法。特别地，本发明涉及式I的脲基和硫脲基哌嗪衍生物。这些化合物具有独特的抗病毒活性，无论是单独使用还是与其他抗病毒药物、抗感染剂、免疫调节剂或HIV进入抑制剂联合使用。更具体地，本发明涉及HIV和艾滋病的治疗。式I的化合物为：其中：Y为O或S；Q选自由m为2的组；A为NR13R14；且-W-为____________。
• Antiviral indoleoxoacetyl piperazine derivatives
  申请人：Bristol-Myers Squibb Company

  公开号：US06469006B1

  公开（公告）日：2002-10-22

  This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with indoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.

  本发明提供了具有药物和生物影响性质的化合物，其制药组合物和使用方法。特别地，本发明涉及到吲哚氧乙酰哌嗪衍生物。这些化合物具有独特的抗病毒活性，无论是单独使用还是与其他抗病毒药物、抗感染药物、免疫调节剂或HIV进入抑制剂联合使用。更具体地，本发明涉及治疗HIV和艾滋病。
• Bicyclic carboxamides and methods of use thereof
  申请人：Tempest Therapeutics, Inc.

  公开号：US10968201B2

  公开（公告）日：2021-04-06

  Compounds, compositions and methods are provided for modulating the activity of EP2 and EP4 receptors, and for the treatment, prevention and amelioration of one or more symptoms of diseases or disorders related to the activity of EP2 and EP4 receptors. In certain embodiments, the compounds are antagonists of both the EP2 and EP4 receptors.

  本发明提供了调节 EP2 和 EP4 受体活性的化合物、组合物和方法，用于治疗、预防和改善与 EP2 和 EP4 受体活性有关的疾病或紊乱的一种或多种症状。在某些实施方案中，化合物是 EP2 和 EP4 受体的拮抗剂。